Hubei Huashitong Biopharmaceutical Technology

Hubei Huashitong Biopharmaceutical Technology is a China-based pharmaceutical company specializing in the development and manufacturing of high-end complex generics and innovative drugs, with a primary focus on nephrology and metabolic diseases. The company has established a comprehensive value chain encompassing R&D, API production, and finished dosage form manufacturing. Its product portfolio includes treatments for hyperphosphatemia, such as Sevelamer Carbonate, and it is actively developing peptide-based therapeutics like Liraglutide and Semaglutide. Huashitong operates GMP-certified facilities and aims to provide affordable, high-quality medications for chronic conditions globally. The company is recognized for its expertise in peptide synthesis and complex formulation technologies.